Old Web
English
Sign In
Acemap
>
authorDetail
>
Jerill Thorpe
Jerill Thorpe
Celgene
Medicine
Oncology
Internal medicine
Lymphocytic lymphoma
Immunology
3
Papers
13
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucel (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
2019
Journal of Clinical Oncology
Tanya Siddiqi
Kathleen A. Dorritie
Jacob D. Soumerai
Deborah M. Stephens
Jason A. Dubovsky
Heidi H. Gillenwater
Lucy Gong
Jerill Thorpe
Lin Yang
William G. Wierda
Show All
Source
Cite
Save
Citations (9)
TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTAGENE MARALEUCEL IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
2019
Hematological Oncology
Tanya Siddiqi
Kathleen A. Dorritie
Jacob D. Soumerai
Deborah M. Stephens
Jason A. Dubovsky
Heidi H. Gillenwater
Lucy Gong
Jerill Thorpe
Lin Yang
William G. Wierda
Show All
Source
Cite
Save
Citations (1)
Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study
2019
Blood
Alison R. Sehgal
John Godwin
John Pribble
Lei Wang
Jerill Thorpe
Gerhard C. Hildebrandt
Show All
Source
Cite
Save
Citations (3)
1